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An imbalance between the production and clearance of macromolecules such as
proteins, lipids and carbohydrates can lead to a category of diseases broadly known as
macromolecule storage disorders. These include, but not limited to, neurodegenerative
diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease associated with
accumulation of aggregation-prone proteins, Lafora and Pompe disease associated
with glycogen accumulation, whilst lipid accumulation is characteristic to Niemann-
Pick disease and Gaucher disease. One of the underlying factors contributing
to the build-up of macromolecules in these storage disorders is the intracellular
degradation pathway called autophagy. This process is the primary clearance route
for unwanted macromolecules, either via bulk non-selective degradation, or selectively
via aggrephagy, glycophagy and lipophagy. Since autophagy plays a vital role in
maintaining cellular homeostasis, cell viability and human health, malfunction of this
process could be detrimental. Indeed, defective autophagy has been reported in a
number of macromolecule storage disorders where autophagy is impaired at distinct
stages, such as at the level of autophagosome formation, autophagosome maturation
or improper lysosomal degradation of the autophagic cargo. Of biomedical relevance,
autophagy is regulated by multiple signaling pathways that are amenable to chemical
perturbations by small molecules. Induction of autophagy has been shown to improve
cell viability and exert beneficial effects in experimental models of various macromolecule
storage disorders where the lysosomal functionality is not overtly compromised. In
this review, we will discuss the role of autophagy in certain macromolecule storage
disorders and highlight the potential therapeutic benefits of autophagy enhancers in
these pathological conditions.
Keywords: autophagy, autophagy inducers, selective autophagy, macromolecule storage disorders,
neurodegenerative disorders, proteinopathies, lipid storage disorders, glycogen storage disorders
THE REGULATION OF AUTOPHAGY
Macroautophagy (herein referred to as autophagy) is an essential process for cellular homeostasis
and survival of the organism. It selectively removes undesirable macromolecules or damaged
organelles which might become toxic if accumulated in the cells, and non-selectively recycles
cytosolic materials during starvation to generate energy (Mizushima, 2018). This process starts
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with the formation of isolated membrane structures in the
cytoplasm called phagophores. The origin of these membrane
structures has been suggested to be from the endoplasmic
reticulum (ER), as well as from other sources like mitochondria,
Golgi apparatus and plasma membrane (Tooze and Yoshimori,
2010; Yu et al., 2018). The phagophores elongate to form double
membrane-bound vesicles called autophagosomes, during which
the autophagic cargo is engulfed. The autophagosomes then
mature to form the degradative autolysosomes either via a multi-
step process by initially fusing with the late endosomes to
form amphisomes and then with the lysosomes, or by directly
fusing with the lysosomes (Nakamura and Yoshimori, 2017). The
autophagic cargo is eventually degraded in the autolysosomes
by the acidic lysosomal enzymes and the breakdown products
are then recycled (Figure 1). These dynamic vesicle fusion
events coupled with cargo clearance are collectively defined as
autophagic flux.
The classical mechanism regulating autophagy is via the
mechanistic target of rapamycin complex 1 (mTORC1) pathway,
which negatively regulates this process under nutrient-rich
conditions (Kim and Guan, 2015). The levels of growth factors,
amino acids and energy status in the cell can also influence
autophagy via mTORC1 (Meijer et al., 2015). Physiologically,
autophagy is stimulated by starvation via inhibition of mTORC1.
Downstream of mTORC1, autophagy initiation is mediated
via the ULK1 complex comprising of ULK1, FIP200, ATG13,
and ATG101 (Zachari and Ganley, 2017). A positive regulator
of autophagy is AMPK, which acts by either inhibiting
mTORC1 or by directly inducing autophagy initiation via
phosphorylation of ULK1 (Russell et al., 2014; Figure 1). Another
downstream target of mTOR that indirectly prevents autophagy
is the phosphorylation and cytoplasm sequestration of TFEB,
which is a transcription factor mediating the expression of
genes related to lysosomal function (Settembre et al., 2013).
Apart from mTORC1-dependent regulation, autophagy can
also be governed by mTORC1-independent pathways such
as increase in the levels of intracellular inositol, IP3, Ca2+,
cAMP and nitric oxide that negatively regulate this process
(Sarkar, 2013; Figure 1). Several autophagy-related (ATG)
proteins in the autophagic machinery mediate the autophagy
initiation steps, such as the ATG12-ATG5-ATG16L1 complex
and phosphatidylethanolamine-conjugated LC3-II; the latter
remains associated with the autophagosomes throughout their
lifespan and acts as a marker of autophagy (Mizushima
et al., 2011; Ktistakis and Tooze, 2016). After autophagosome
biogenesis, their lysosomal delivery and fusion are mediated by
various factors including SNAREs (syntaxin 17 and SNAP29
on autophagosomes, and lysosomal VAMP8), HOPS (homotypic
fusion and protein sorting) complex, Rab7, GABARAPs, BRUCE,
and Beclin1-interacting partners such as ATG14L and UVRAG
(Wang et al., 2016; Reggiori and Ungermann, 2017; Figure 1).
Since autophagy is implicated in myriad human diseases,
small molecule autophagy modulators have potential biomedical
relevance (Rubinsztein et al., 2012; Sarkar, 2013; Panda et al.,
2019). Autophagy can be modulated pharmacologically either
via inhibiting mTORC1 or independently of mTORC1. The
commonly-used mTOR inhibitors for inducing autophagy are
rapamycin (Blommaart et al., 1995) and its ester analog CCI-
779 (Ravikumar et al., 2004), and Torin 1 (Thoreen et al.,
2009). There are several ways of inducing mTOR-independent
autophagy, such as with carbamazepine (inositol lowering agent)
(Sarkar et al., 2005), trehalose (AMPK activator) (Sarkar et al.,
2007a; DeBosch et al., 2016), rilmenidine (cAMP reducing agent)
(Williams et al., 2008), verapamil and felodipine (Ca2+ channel
blockers) (Williams et al., 2008; Siddiqi et al., 2019), amongst
others (Figure 1). Additional means include the autophagy-
inducing peptide, Tat-Beclin 1 (Shoji-Kawata et al., 2013). From
a clinical perspective, since mTOR regulates critical cellular
processes such as protein translation and cell growth, inducing
autophagy independent of mTOR is considered to be a safer
approach with lesser side-effects for biomedical applications
(Rubinsztein et al., 2012; Sarkar, 2013).
THE ROLE OF AUTOPHAGY IN
MACROMOLECULE STORAGE
DISORDERS
An imbalance between the production and clearance of
macromolecules, causing their intracellular accumulation, can
lead to a category of diseases broadly known as macromolecule
storage disorders. Autophagy is a major clearance route for
a wide spectrum of macromolecules such as proteins, lipids
and carbohydrates, either via non-selective bulk degradation or
selectively via aggrephagy (for aggregated proteins), lipophagy
(for lipids), and glycophagy (for glycogen) (Stolz et al., 2014;
Gatica et al., 2018). Decline in the functionality of autophagy
contributes to the build-up of macromolecular materials that
could be deleterious to the cells. Indeed, impairment in
autophagic flux has been reported in a number of macromolecule
storage disorders (Table 1). In these conditions, the defect in
autophagy could occur at distinct stages: inhibition in the early
stages related to autophagosome formation, or impairment in
the late stages involving autophagosome maturation, lysosomal
function and autophagic cargo clearance (Figure 2). Since
autophagy is a vital homeostatic mechanism, compromised
autophagy reduces cell viability and contributes to the disease
pathology (Green and Levine, 2014; Jiang and Mizushima,
2014). Of biomedical relevance, pharmacological induction
of autophagy has been shown to improve cell viability
and exert beneficial effects in transgenic animal models of
some macromolecular storage disorders where the lysosomal
functionality is not overtly compromised (Table 1; Rubinsztein
et al., 2012; Sarkar, 2013; Levine et al., 2015; Seranova et al., 2017;
Panda et al., 2019). We will discuss below the role of autophagy in
few macromolecular storage disorders and highlight the potential
therapeutic benefits of autophagy enhancers in these conditions.
THE ROLE OF AUTOPHAGY IN
PROTEINOPATHIES
Accumulation of aggregated proteins in the brain causes
neurodegenerative disorders that are collectively termed
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FIGURE 1 | Regulation of the mammalian autophagy pathway. Autophagy initiates by the formation of phagophore that expands and engulfs autophagic cargo to
form autophagosome, which then matures to form autolysosome, either by initially fusing with the late endosome to form amphisome and then with the lysosome, or
by directly fusing with the lysosome. Selective autophagic cargo includes aggregation-prone proteins, damaged mitochondria, lipid droplets and glycogen, as well as
the autophagy receptor protein p62; all of which are degraded in the autolysosome. Several ATG proteins including the ATG12-ATG5-ATG16L1 complex and LC3-II
mediate the initiation of autophagy. LC3-II remains on the autophagosome throughout its lifespan and is thus used as a marker for autophagy. The classical regulator
of autophagy is mTORC1, which negatively regulates autophagy by inhibiting the ULK1 complex. However, AMPK can positively regulate autophagy by directly
phosphorylating ULK1. The mTORC1-independent regulators of autophagy include elevated intracellular levels of IP3, Ca2+, and cAMP; all of which are autophagy
inhibitory signals. Autophagosome maturation in the late stage of autophagy is governed by various factors including SNAREs, HOPS complex, Rab7, GABARAPs,
and ATG14L, amongst others. Autophagy can be induced pharmacologically by mTOR inhibitors (rapamycin, torin1), as well as by mTOR-independent inducers
such as via AMPK activators (trehalose), and via agents lowering IP3 (carbamazepine), Ca2+ (verapamil, felodipine), and cAMP (rilmenidine) levels (reduction in
second messenger molecules indicated by red arrows). Abbreviations - AMPK, 5′ adenosine monophosphate-activated protein kinase; ATG, Autophagy related;
Ca2+, Calcium; cAMP, 3′,5′-cyclic adenosine monophosphate; FIP200, FAK family kinase-interacting protein of 200 kDa; GABARAP, γ-aminobutyric acid
receptor-associated protein; HOPS, Homotypic fusion and protein sorting complex; IP3, Inositol 1,4,5-trisphosphate; mTORC1, Mechanistic target of rapamycin
complex 1; SNARE, Soluble N-ethylmaleimide-sensitive factor activating protein receptor.
proteinopathies. Autophagy is the primary clearance mechanism
for several aggregation-prone proteins, such as amyloid-β,
α-synuclein and huntingtin, associated with Alzheimer’s,
Parkinson’s and Huntington’s disease, respectively (Nixon, 2013;
Menzies et al., 2017); a process termed aggrephagy (Gatica et al.,
2018). The misfolded proteins that are targeted for autophagic
degradation are ubiquitinated (Grumati and Dikic, 2018). The
autophagy cargo receptors, p62 (SQSTM1) (Pankiv et al., 2007),
NBR1 (Kirkin et al., 2009), optineurin (Korac et al., 2013), and
TOLLIP (Lu et al., 2014), recruit the ubiquitinated cargo to the
autophagosomes via their respective ubiquitin-binding domain
and LC3-interacting region (LIR), whereas WDFY3 (also known
as ALFY) acts as a scaffold for aggrephagy (Filimonenko et al.,
2010). Importantly, basal autophagy is critical for maintaining
cellular homeostasis in post-mitotic neurons since abrogation
of this process in normal mouse brain led to neurodegeneration
(Hara et al., 2006; Komatsu et al., 2006); implicating that
defective autophagy in neurodegenerative diseases is a major
contributing factor. While autophagy dysfunction has been
reported in almost all neurodegenerative diseases studied, few
common proteinopathies where autophagy induction could be
beneficial are discussed below.
Alzheimer’s Disease and Tauopathies
The commonest cause of progressive dementia is Alzheimer’s
disease (AD), characterized by abnormal metabolism of amyloid
precursor protein (APP) that leads to the formation of
extracellular senile plaques made of amyloid-β (Aβ) (Selkoe and
Hardy, 2016). Autophagy has a role in the generation, clearance
and secretion of Aβ: Aβ has been suggested to be generated inside
autophagosomes containing APP and the enzyme presenilin-1
(PS-1) that cleaves APP into Aβ; Aβ is degraded via autophagy;
and Aβ is possibly secreted to extracellular space via autophagy
where it forms plaques (Yu et al., 2005; Nilsson et al., 2013;
Tian et al., 2013). In addition, autophagy is dysregulated at
multiple stages depending on the gene mutation or the disease
agent in AD (Nixon, 2013). Mutations in PS-1 gene, encoding
for presenilin-1, impaired lysosomal acidification and function
that blocked autophagic flux and prevented autophagosome
maturation (Figure 2) because PS1 is required for targeting
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of v-ATPase V0a1 subunit to the lysosomes for maintaining
lysosomal pH (Lee et al., 2010; Wolfe et al., 2013). Indeed,
accumulation of autophagosomes was seen in AD patient brain
and in dystrophic neurites of PS1/APP mice (Boland et al.,
2008). On the contrary, decrease in beclin-1, which regulates
autophagosome formation, was found in the affected areas of AD
patient brain that could be due to activated caspase-3 cleavage
(Pickford et al., 2008; Rohn et al., 2011).
The presence of intracellular neurofibrillary tangles made
of hyper-phosphorylated tau, a microtubule-associated protein,
is another hallmark of AD and also for tauopathies including
frontotemporal dementias (FTDs) (Spillantini and Goedert,
2013). Mutant tau possibly retards autophagosome–lysosome
fusion (Figure 2) by impairing the retrograde axonal transport
via the dynein/dynactin complex, as seen in FTD flies and mice
(Majid et al., 2014; Butzlaff et al., 2015). In addition, mutant
tau colocalized with autophagic vesicles and the aggrephagy
receptor protein p62 (Piras et al., 2016), and is likely degraded
by autophagy (Berger et al., 2006; Wang et al., 2009).
Chemical or genetic upregulation of autophagy has been
shown to be beneficial in transgenic models of AD and tauopathy.
Rapamycin reduced Aβ plaques and tau tangles and rescued their
pathology in APP/Tau/PS1 mutant (3xTg-AD) mice (Caccamo
et al., 2010; Majumder et al., 2011), APP/PS1 mutant mice (Jiang
et al., 2014a), APP mutant mice (Spilman et al., 2010), APOE4
mutant mice (Lin et al., 2017), FTD mice (Wang et al., 2012),
and mutant tau mice (Ozcelik et al., 2013; Jiang et al., 2014b;
Siman et al., 2015) and Drosophila (Berger et al., 2006). One
of the studies indicated that rapamycin was effective at early
stages but not after the plaques and tangles were established
(Majumder et al., 2011). Likewise, the mTOR-independent
autophagy enhancers, trehalose and carbamazepine, were also
effective in clearing these toxic species and improving the disease
pathology. Trehalose was beneficial in APP/PS1 mutant mice
(Du et al., 2013), APP mutant mice (Portbury et al., 2017) and
mutant tau mice (Rodriguez-Navarro et al., 2010; Schaeffer et al.,
2012), while carbamazepine in APP/PS1 mice (Tardiff et al.,
2013), 3xTg-AD mice (Zhang et al., 2017), and FTD mice (Wang
et al., 2012). Additional autophagy-inducing compounds, such as
SMER28, latrepirdine and gypenoside XVII (GP-17), were also
shown to reduce Aβ levels and improve AD pathology (Tian
et al., 2011; Steele et al., 2013; Meng et al., 2016). Genetically,
overexpression of beclin-1 or TFEB reduced the levels and
pathology of Aβ and tau in APP mutant mice (Pickford et al.,
2008) or in mutant APP/PS1 and mutant tau mice (Polito et al.,
2014; Xiao et al., 2014), respectively. As a likely consequence
of disrupted autophagy, mitophagy is also affected in AD and
is associated with mitochondrial dysfunction and bioenergetics
deficits (Kerr et al., 2017); whereas stimulation of mitophagy
rescued the AD pathology in APP/PS1 mutant mice (Fang et al.,
2019). Overall, multiple studies have pointed that stimulating
autophagy could be beneficial in AD.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder characterized by motor deficits
and cognitive decline (Baizabal-Carvallo and Jankovic, 2016).
The commonly-mutated genes in familial PD encode for
α-synuclein, PINK1, Parkin, and LRKK2, which have been
shown to deregulate autophagy and mitophagy that contribute to
the underlying neurodegeneration (Karabiyik et al., 2017). The
α-synuclein inclusions, also called Lewy bodies that are hallmark
of PD, impaired autophagosome maturation without affecting
lysosomal function (Tanik et al., 2013). However, overexpression
of α-synuclein (comparable to its gene multiplication in PD) in
cells and transgenic mice suppressed autophagosome formation
(Figure 2) by mislocalization of ATG9 (Winslow et al., 2010),
and also by cytoplasmic retention of TFEB (Decressac et al.,
2013). Similar trafficking defect of ATG9 resulting in autophagy
inhibition was seen with mutant VPS35, which causes an
autosomal dominant form of PD (Zavodszky et al., 2014).
Additionally, mutations or depletion of PD-associated LRRK2,
ATP13A2, and STY11 have been suggested to impair autophagy
(Bento et al., 2016; Manzoni and Lewis, 2017). The A53T and
A30P point mutants of α-synuclein, however, mediated their
toxic effects by impairing another form of autophagy called
chaperone-mediated autophagy (CMA), which involves direct
protein translocation across lysosomal membrane (Cuervo et al.,
2004; Martinez-Vicente et al., 2008). Apart from the defects in
autophagy and CMA in PD, compelling studies demonstrate
a direct role of PD-associated mutant proteins in disrupting
mitophagy. PINK1 and Parkin, which are commonly mutated
in autosomal recessive juvenile PD, normally functions in
maintaining mitochondrial quality control (Youle and Narendra,
2011). Damaged mitochondria accumulate PINK1 on its outer
membrane that recruits and activates the E3 ubiquitin ligase
Parkin, which then ubiquitinates outer mitochondrial membrane
proteins to initiate selective mitophagy (Pickrell and Youle,
2015). Pathogenic mutations in PINK1 and Parkin impair
mitophagy (Figure 2), which is associated with mitochondrial
dysfunction, oxidative stress and mitochondrial DNA mutations
(Bender et al., 2006; Geisler et al., 2010; Narendra et al., 2010;
Bose and Beal, 2016).
Despite autophagy defects in PD, induction of autophagy
could promote autophagic clearance of α-synuclein mutants
(Webb et al., 2003), and has been shown to be beneficial in toxin-
induced or transgenic mouse models of PD. Genetic activation of
autophagy in α-synuclein transgenic mice or rats by Beclin-1 or
TFEB overexpression, respectively, decreased α-synuclein levels
and ameliorated neuropathology (Spencer et al., 2009; Decressac
et al., 2013). Pharmacologically, rapamycin rescued disease
progression, neuronal loss and mitochondrial dysfunction in
MPTP-treated PD mouse models (Malagelada et al., 2010; Liu
et al., 2013) and A53T α-synuclein transgenic mice (Bai et al.,
2015), improved non-motor behavioral changes in 6-OHDA
treated PD mouse model (Masini et al., 2018), and prevented
dyskinesia in L-DOPA-treated mouse model of Parkinsonism
(Santini et al., 2009). An additive effect of rapamycin and
trehalose has been demonstrated in inducing autophagy, which
was neuroprotective in MPTP-treated PD mice (Pupyshev
et al., 2019). Although trehalose could induce autophagy in
human and other mammalian cell lines, mouse brain and
iPSC-derived neurons, and has been robustly demonstrated
to be effective against neurodegeneration by various studies
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Autophagy inducers and their mechanisms of
action
Therapeutic benefits in vivo or in iPSC
models
Proteinopathies
Alzheimer’s disease (AD) and tauopathy
PS1
Tau
Defective autophagy due to impaired
autophagosome maturation;
mechanism via impairment in lysosomal
acidification due to improper lysosomal
targeting of v-ATPase V0a1 subunit
(Lee et al., 2010; Wolfe et al., 2013)
Defective autophagy possibly due to
impaired autophagosome maturation;
mechanism via disruption of axonal
transport (Majid et al., 2014; Butzlaff
et al., 2015)
Rapamycin: Induces autophagy by mTORC1 inhibition
(Blommaart et al., 1995)
AD mice (APP/Tau/PS1 mutant) (Caccamo
et al., 2010; Majumder et al., 2011), AD mice
(APP/PS1 mutant) (Jiang et al., 2014a), AD
mice (APP mutant) (Spilman et al., 2010), AD
mice (APOE4 mutant) (Lin et al., 2017), FTD
mice (TDP-43) (Wang et al., 2012), FTD mice
(tau mutant) (Ozcelik et al., 2013; Jiang et al.,
2014b; Siman et al., 2015), FTD Drosophila
(Berger et al., 2006)
Carbamazepine: Induces mTOR-independent
autophagy by lowering inositol and IP3 (Sarkar et al.,
2005)
AD mice (APP/PS1 mutant) (Tardiff et al., 2013),
AD mice (APP/Tau/PS1 mutant) (Zhang et al.,
2017), FTD mice (TDP-43) (Wang et al., 2012)
Trehalose: Induces mTOR-independent autophagy via
AMPK activation (Sarkar et al., 2007a; DeBosch et al.,
2016)
AD mice (APP/PS1 mutant) (Du et al., 2013),
AD mice (APP mutant) (Portbury et al., 2017),
FTD mice (tau mutant) (Rodriguez-Navarro
et al., 2010; Schaeffer et al., 2012)
Latrepirdine: Induces autophagy by inhibition of
mTORC1 signaling (Steele et al., 2013)
AD mice (APP mutant) (Steele et al., 2013)
Gypenoside XVII (GP-17): Induces autophagy by TFEB
nuclear translocation (Meng et al., 2016)
AD mice (APP/PS1 mutant) (Meng et al., 2016)
Parkinson’s disease (PD)
α-syn α-syn overexpression causes defective
autophagy due to impaired
autophagosome formation; mechanism
via ATG9 mislocalization (Winslow et al.,
2010) and cytoplasmic retention of
TFEB (Decressac et al., 2013); whereas
A53T and A30P α-syn mutants impair
CMA (Cuervo et al., 2004;
Martinez-Vicente et al., 2008)
Rapamycin: Induces autophagy by mTORC1 inhibition
(Blommaart et al., 1995)
PD mice (A53Tα-syn) (Bai et al., 2015), PD
mice (MPTP treated) (Malagelada et al., 2010;
Liu et al., 2013), PD mice (6-OHDA treated)
(Masini et al., 2018), PD mice (L-DOPA treated)
(Santini et al., 2009)
Parkin,
PINK1
Defective mitophagy due to impaired
targeting of damaged mitochondria to
autophagosomes (Geisler et al., 2010;
Narendra et al., 2010)
Felodipine: Induces mTOR-independent autophagy by
lowering cytosolic Ca2+ (Siddiqi et al., 2019)
PD mice (A53Tα-syn), A53T α-syn
iPSC-derived neurons (Siddiqi et al., 2019)
6-Bio: Induces autophagy by inhibition of mTORC1
signaling (Suresh et al., 2017)
PD mice (MPTP treated) (Suresh et al., 2017)
Piperlongumine: Induces autophagy by Bcl2
phosphorylation and Bcl2-Beclin1 dissociation
(Liu et al., 2018)
PD mice (rotenone treated) (Liu et al., 2018)
Huntington’s disease (HD)
HTT Defective autophagy due to impaired
recognition of autophagic cargo
(Martinez-Vicente et al., 2010) and
disrupted axonal transport (Wong and
Holzbaur, 2014)
Rapamycin, CCI-779: Induces autophagy by mTORC1
inhibition (Blommaart et al., 1995; Ravikumar et al.,
2004)
HD mice (HD-N171–82Q) (Ravikumar et al.,
2004), HD Drosophila (Ravikumar et al., 2004;
Sarkar et al., 2008), HD zebrafish (Williams
et al., 2008)
Trehalose: Induces mTOR-independent autophagy via
AMPK activation (Sarkar et al., 2007a; DeBosch et al.,
2016)
HD mice (HD-ex1–145Q) (Tanaka et al., 2004)a
Rilmenidine: Induces mTOR-independent autophagy by
lowering cAMP (Williams et al., 2008)
HD mice (HD-N171–82Q) (Rose et al., 2010)
(Continued)
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TABLE 1 | Continued
Mutant proteins Autophagy defects and
mechanisms
Autophagy inducers and their mechanism
of action
Therapeutic benefits in vivo or in iPSC
models
Felodipine: Induces mTOR-independent
autophagy by lowering cytosolic Ca2+ (Siddiqi
et al., 2019)
HD mice (HD-N171–82Q), HD zebrafish (Siddiqi
et al., 2019)
SMER28: Induces mTOR-independent
autophagy (Sarkar et al., 2007b); mechanism
not known
HD Drosophila (Sarkar et al., 2007b)
AUTEN-67, AUTEN-99: Induce autophagy by
MTMR14 inhibition (Billes et al., 2016; Kovacs
et al., 2017)
HD Drosophila (Billes et al., 2016;
Kovacs et al., 2017)
L-NAME: Induce mTOR-independent
autophagy by NOS inhibition (Sarkar et al.,
2011)
HD Drosophila, HD zebrafish
(Sarkar et al., 2011)
Verapamil: Induces mTOR-independent
autophagy by lowering cytosolic Ca2+ (Williams
et al., 2008)
HD Drosophila, HD zebrafish
(Williams et al., 2008)
Lipid storage disorders
Niemann Pick type C disease (NPC)
NPC1 Defective autophagy due to impaired
autophagosome maturation;
mechanism via failure in SNARE
machinery (Sarkar et al., 2013),
reduction in SphK activity, and VEGF
levels (Lee H. et al., 2014)
Rapamycin: Induces autophagy by mTORC1
inhibition (Blommaart et al., 1995)
NPC1 iPSC-derived neurons and hepatic cells
(Maetzel et al., 2014)
NPC2 Defective autophagy possibly due to
impaired autophagosome maturation
(Guo et al., 2016); mechanism not
known
Carbamazepine: Induces mTOR-independent
autophagy by lowering inositol and IP3 (Sarkar
et al., 2005)
NPC1 iPSC-derived neurons and hepatic cells
(Maetzel et al., 2014)
Trehalose: Induces mTOR-independent
autophagy via AMPK activation (Sarkar et al.,
2007a; DeBosch et al., 2016)
NPC1 iPSC-derived neurons (Maetzel et al.,
2014)
Verapamil: Induces mTOR-independent
autophagy by lowering cytosolic Ca2+ (Williams
et al., 2008)
NPC1 iPSC-derived neurons (Maetzel et al.,
2014)
BRD5631: Induces mTOR-independent
autophagy (Kuo et al., 2015); mechanism not
known
NPC1 iPSC-derived neurons (Kuo et al., 2015)
Gaucher’s disease (GD)
GCase Defective autophagy possibly due to
impaired autophagosome maturation
(Sun et al., 2010); mechanism not
known but suggested via lysosomal
defect (Osellame et al., 2013)
Rapamycin: Induces autophagy by mTORC1
inhibition (Blommaart et al., 1995)
GD Drosophila (Kinghorn et al., 2016)b
Sap C Defective autophagy possibly due to
impaired autophagosome maturation;
mechanism not clear but suggested via
inefficient cathepsin activity (Tatti et al.,
2012)
Fabry disease (FD)
α-Gal A Defective autophagy possibly due to
impaired autophagosome maturation
(Chevrier et al., 2010); mechanism not
known
Not tested Not tested
(Continued)
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TABLE 1 | Continued
Mutant proteins Autophagy defects and
mechanisms
Autophagy inducers and their mechanism
of action






Defective autophagy due to impaired
autophagosome formation; mechanism
via mTOR activation (Aguado et al.,
2010)
Defective autophagy due to impaired
autophagosome formation (Criado
et al., 2012); mechanism not known
Metformin: Induces autophagy by AMPK
activation (Buzzai et al., 2007)
LD mice (Epm2a−/−) (Berthier et al., 2016)c
Von Gierke’s disease (GSDIa)
G6PC Defective autophagy due to impaired
autophagosome formation; mechanism
via mTOR activation, AMPK inhibition
(Farah et al., 2016), SIRT1
downregulation (Cho et al., 2017)
Rapamycin: Induces autophagy by mTORC1
inhibition (Blommaart et al., 1995)
Bezafibrate: PPAR agonist but
autophagy-inducing mechanism not clear
(Waskowicz et al., 2019)
GSDIa mice (G6pc−/−) (Farah et al., 2016,
2017); GSDIa dogs (Farah et al., 2016)
GSDIa mice (G6pc−/−) (Waskowicz et al.,
2019)
Pompe disease (GSDII)
GAA Defective autophagy possibly due to
impaired autophagosome maturation
(Raben et al., 2008; Nascimbeni et al.,
2012); mechanism not known
Rapamycin: Induces autophagy by mTORC1
inhibition (Blommaart et al., 1995)
GSDII mice (Gaa−/−) (Ashe et al., 2010)
AD, Alzheimer’s disease; AMPK, 5′ adenosine monophosphate-activated protein kinase; APP, Amyloid precursor protein; AUTEN, Autophagy enhancer; Ca2+, Calcium;
cAMP, 3′,5′-cyclic adenosine monophosphate; FD, Fabry disease; FTD, Frontotemporal dementia; α-Gal A, α-galactosidase A; GAA, Acid α-glucosidase; GCase,
Glucocerebrosidase; GD, Gaucher disease; G6PC, Glucose-6-phosphatase-α; GSDIa, Glycogen storage disease type Ia; GSDII, Glycogen storage disease type II;
HD, Huntington’s disease; HTT, Huntingtin; IP3, Inositol 1,4,5-trisphosphate; iPSC, Induced pluripotent stem cells; LD, Lafora disease; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; MTMR14, Myotubularin related protein 14; mTORC1, Mechanistic target of rapamycin complex 1; NOS, Nitric oxide synthase; NPC, Niemann-Pick
type C; 6-OHDA, 6-hydroxydopamine; PD, Parkinson’s disease; PINK1, PTEN-induced kinase 1; PPAR, Peroxisome proliferator-activated receptor; PS1, Presenilin-1;
Sap C, Saposin C; SMER, Small molecule enhancer of rapamycin; SphK, Sphingosine kinase; α-syn, α-synuclein; TDP-43, Transactive response DNA binding protein
43 kDa; TFEB, Transcription factor EB; VEGF, Vascular endothelial growth factor. aProtective effects of trehalose could be due to its chaperone-like ability to stabilize
unfolded proteins (Tanaka et al., 2004). bRapamycin was cytotoxic in GD iPSC-derived neurons (Awad et al., 2015). cProtective effects of metformin in LD may not be
due to autophagy induction (Berthier et al., 2016).
(Hosseinpour-Moghaddam et al., 2018), a recent report indicated
that trehalose and other disaccharides could block autophagy and
increase α-synuclein aggregation in immortalized human cells or
rat cortical neurons (Yoon et al., 2017). Nonetheless, trehalose
and several other mTOR-independent autophagy inducers like
verapamil, rilmenidine, valproate and calpastatin could enhance
the clearance of α-synuclein mutants (Webb et al., 2003; Sarkar
et al., 2007a; Williams et al., 2008). Another autophagy inducer
called 6-Bio, which acts by inhibiting mTORC1 signaling,
enhanced α-synuclein clearance and ameliorated toxicity in
MPTP-treated PD mice (Suresh et al., 2017). Other autophagy-
inducing compounds like metformin, piperlongumine and
nilotinib were also protective in PD mice (Hebron et al.,
2014; Liu et al., 2018; Ryu et al., 2018). Interestingly, retinoic
acid derivatives such as AR7, GR1 and GR2 were shown to
activate CMA for lowering α-synuclein levels and improving
cell viability in a PD cell model expressing α-synuclein
(Anguiano et al., 2013).
Huntington’s Disease
Huntington’s disease (HD) is a monogenic, autosomal dominant,
neurodegenerative disorder characterized by motor and
cognitive deficits. HD is caused by expansion of CAG repeats
in HTT gene, resulting in polyglutamine-expanded mutant
huntingtin protein that is aggregation-prone, cytotoxic
(Zoghbi and Orr, 2000), and is predominantly degraded by
autophagy (Ravikumar et al., 2002). Despite accumulation of
autophagosomes in HD models (Kegel et al., 2000; Petersen
et al., 2001), defective autophagy in HD is attributed to
failure in autophagic cargo recognition. Mutant huntingtin
impairs the recognition and recruitment of autophagic cargo
by autophagosomes (Martinez-Vicente et al., 2010; Figure 2),
whereas wild-type huntingtin acts as a scaffold for recruiting
autophagic proteins during selective autophagy such as
aggrephagy and mitophagy (Ochaba et al., 2014; Rui et al.,
2015). In addition, mutant huntingtin was also reported to
perturb the axonal transport of autophagosomes that affected
cargo degradation (Wong and Holzbaur, 2014), which was
also retarded by decreased dynein function that prevented
the clearance of aggregation-prone proteins and augmented
toxicity (Ravikumar et al., 2005). Although mutant huntingtin
is an established autophagy substrate (Sarkar and Rubinsztein,
2008), a recent study suggested that the conformation of mutant
huntingtin dictates its ability to be cleared by autophagy. A toxic
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FIGURE 2 | Impairment of autophagy in macromolecule storage disorders. Autophagy initiates by the formation of phagophore that expands and engulfs autophagic
cargo to form autophagosome, which then matures to form autolysosome, either by initially fusing with the late endosome to form amphisome and then with the
lysosome, or by directly fusing with the lysosome. Selective autophagic cargo includes aggregation-prone proteins, damaged mitochondria, lipid droplets and
glycogen, as well as the autophagy receptor protein p62. LC3-II is used as a marker for autophagy as it remains on the autophagosome throughout its lifespan.
Impairment of autophagy at distinct stages, such as autophagosome formation, cargo recognition and autophagosome maturation, caused due to the mutant
proteins associated with various macromolecule storage disorders are indicated (red lines). Pharmacological induction of autophagy (blue arrow) by autophagy
inducers (in blue box) exerts therapeutic benefits in transgenic models of many of these diseases. Abbreviations – AD, Alzheimer’s disease; FD, Fabry disease; FTD,
Frontotemporal dementia; GD, Gaucher disease; GSDIa, Glycogen storage disease type Ia; GSDII, Glycogen storage disease type II; HD, Huntington’s disease; LD,
Lafora disease; mTOR, Mechanistic target of rapamycin; NPC, Niemann-Pick type C; PD, Parkinson’s disease; PINK1, PTEN-induced kinase 1.
form of mutant huntingtin, recognized by the polyglutamine
antibody 3B5H10, was found to lack Lys63 polyubiquitination
that is essential to interact with p62/SQSTM1 for selective
autophagy (Fu et al., 2017).
Nonetheless, pharmacological stimulation of autophagy
enhances the clearance of mutant huntingtin preferentially
over its wild-type counterpart (Ravikumar et al., 2002), and
the beneficial effects of autophagy induction are robustly
demonstrated in cell, Drosophila, zebrafish and mouse
models of HD (Sarkar et al., 2009). Amelioration of disease
phenotypes in HD mice with autophagy-inducing compounds
has been shown with rapamycin (Ravikumar et al., 2004),
trehalose (Tanaka et al., 2004), rilmenidine (Rose et al., 2010),
calpastatin (Menzies et al., 2015), and recently, with the
anti-hypertensive drug felodipine at pharmacokinetics similar
to its conventional application in humans (Siddiqi et al.,
2019); and also in HD fly models with SMERs (Sarkar et al.,
2007b), L-NAME (Sarkar et al., 2011), AUTEN-67 (Billes
et al., 2016), AUTEN-99 (Kovacs et al., 2017), verapamil and
valproate (Williams et al., 2008). A combination strategy
for maximal stimulation of autophagy via mTOR inhibition
and mTOR-independent routes was more effective in HD
Drosophila than either approach (Sarkar et al., 2008). Overall,
modulation of autophagy presents an attractive treatment option
for HD patients.
THE ROLE OF AUTOPHAGY IN
GLYCOGEN STORAGE DISORDERS
The selective clearance of carbohydrates such as glycogen
via autophagy is termed glycophagy, which plays a crucial
role in glucose homeostasis (Zirin et al., 2013; Zhao et al.,
2018). The starch-binding domain-containing protein 1 (STBD1)
has been identified as the receptor for selective glycophagy.
STBD1 captures glycogen particles to autophagosomes by
interacting with glycogen via its glycan-binding domain and with
GABARAPL1 via its LIR motif (Jiang et al., 2011; Zhu et al.,
2014). Improper glycophagy in glycogen storage disorders may
contribute to the disease pathology (Zhao et al., 2018).
Lafora Disease
Lafora disease (LD) is an autosomal recessive myoclonus epilepsy
characterized by neurodegeneration and intracellular inclusions
of poorly-branched glycogen deposits called Lafora bodies
(Nitschke et al., 2018). The commonly-mutated genes are EPM2A
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and EPM2B that encode laforin (phosphatase) and malin (E3
ubiquitin ligase), respectively, which together functions in the
ubiquitin-proteasome system for promoting misfolded protein
clearance (Garyali et al., 2009). Knockout of these genes in
mice inhibited autophagosome formation (Figure 2), suggesting
impairment of autophagy in LD that was also observed in
patient fibroblasts (Aguado et al., 2010; Criado et al., 2012;
Duran et al., 2014). Mutant laforin suppressed autophagy by
activating mTOR, whereas overexpression of wild-type laforin
induced autophagy by inhibiting mTOR (Aguado et al., 2010).
Activation of mTOR in laforin-deficient cells further activated
serum/glucocorticoid-induced kinase 1 (SGK1), and suppression
of SGK1 activity could lower glycogen accumulation, inhibited
mTOR and rescued the autophagy defect (Singh et al., 2013).
Defective autophagic flux could lead to inefficient glycophagy and
build-up of Lafora bodies that have neurotoxic effects (Duran
et al., 2014); additionally, was also associated with impaired
mitophagy, increased mitochondrial fragmentation and ROS
production, and decreased ATP levels in laforin- and malin-
deficient cells (Roma-Mateo et al., 2015; Upadhyay et al., 2017;
Lahuerta et al., 2018).
Expression of the wild-type or phosphatase-inactive mutant
of laforin corrected glycogen branching, restored functional
autophagy and reduced LB formation in Epm2a−/− mice
(Gayarre et al., 2014), suggesting that abnormal glycogen
accumulation in LD is likely via malfunction of cellular
proteostasis and not due to glycogen dephosphorylation by
laforin. These studies implicate defective autophagy in the
pathogenesis of LD. Although a study has shown that metformin
(AMPK activator and autophagy inducer) reduced LBs and
neurodegeneration in Epm2a−/− mice, the beneficial effects
of this compound were not attributed to autophagy induction
because it did not affect autophagy in vivo (Berthier et al.,
2016). Nonetheless, since autophagy induction could have
potential benefits by facilitating LB clearance and delaying
neurodegeneration, further drug trials in LD mice are required
to demonstrate whether this would be a therapeutic strategy.
Pompe Disease
Pompe disease, also known as glycogen storage disease type II
(GSDII), is an autosomal recessive glycogen storage disorder
that affects muscle and nerve cells, and cause muscle weakness.
GSDII is caused by mutations in the gene encoding for acid
α-glucosidase (GAA), a lysosomal glycogen hydrolase. GAA
normally degrades glycogen, but its mutations lead to glycogen
accumulation in the lysosomes especially in cardiac and skeletal
muscles (Raben et al., 2002). Accumulation of autophagosomes
and autophagy substrates as well as vacuolization, enlarged
lysosomes and improper lysosomal acidification were found in
the myotubes of patients and primary myoblasts of Gaa-deficient
mice (Fukuda et al., 2006b; Raben et al., 2008; Takikita et al., 2009;
Nascimbeni et al., 2012); implicating a block in autophagy at late
stage (Figure 2). This is associated with inefficient mitophagy and
impaired mitochondrial function (Lim et al., 2015). Moreover,
since autophagy has been shown to influence GAA maturation
and glycogen clearance (Nascimbeni et al., 2012; Zirin et al., 2013;
Zhao et al., 2018), dysfunctional autophagy probably contributes
to the pathogenesis of GSDII. In addition, mTOR activity was
suppressed in the myotubes of Gaa-deficient mice where mTOR
remained on the lysosomes even during starvation; and these
effects including autophagosome accumulation were rescued by
genetic reactivation of mTOR (Lim et al., 2017).
A common treatment for GSDII is the enzyme replacement
therapy (ERT) (Desnick and Schuchman, 2012), but its efficiency
is variable and temporary that has been suggested to depend
on the degree of autophagy dysfunction. This is because the
trafficking and processing of the recombinant human GAA seems
to be affected by autophagy (Fukuda et al., 2006a; Nascimbeni
et al., 2015). Autophagy activation by itself, either genetically
via TFEB or TFE3 overexpression or pharmacologically with
rapamycin, reduced glycogen and autophagosome load by
promoting autophagosome maturation and lysosomal exocytosis
in the myotubes of GSDII mice and patients and in iPSC-
derived skeletal muscles (Ashe et al., 2010; Medina et al.,
2011; Nascimbeni et al., 2012; Spampanato et al., 2013;
Martina et al., 2014; Sato et al., 2016). Therefore, combination of
ERT with autophagy induction may be more effective. Indeed,
combining rapamycin or CCI-779 treatment with ERT reduced
muscle glycogen levels in GSDII mice more than either treatment
alone (Ashe et al., 2010). These studies highlight the therapeutic
importance of autophagy in GSDII.
Von Gierke’s Disease
Von Gierke’s disease, also known as glycogen storage disorder
type Ia (GSDIa), is an autosomal recessive disorder associated
with hepatomegaly and kidney failure with symptoms including
hypoglycemia, lactic acidosis and hyperlipidemia. GSDIa is
characterized by glucose-6-phosphatase-α (G6PC) deficiency and
decreased ability of the liver and kidney to break down glycogen
into glucose that causes build-up of glycogen and triglycerides
(Chou et al., 2010). Autophagy has been shown to be suppressed
(Figure 2) in hepatic cell and mouse (G6pc−/−) models of
GSDIa possibly via activation of mTOR, inhibition of AMPK
and reduced nuclear localization of TFEB (Farah et al., 2016).
Likewise, increased acetyl coenzyme A in GSDIa could also
have the same effect (Chou et al., 2010; Marino et al., 2014).
Additionally, G6pc−/− mice also exhibited defective autophagy
in the liver via downregulation of sirtuin-1 (SIRT1) (Cho
et al., 2017), an enzyme which stimulates autophagy directly by
deacetylation of ATG proteins and indirectly by deacetylation
and activation of FoxO transcription factors that transactivate
autophagy genes (Ng and Tang, 2013). Indeed, impaired
autophagy in G6pc−/− mouse liver was attributed to increased
acetylation of Atg5 and Atg7, decreased Atg5-Atg12 conjugation
and reduced autophagosome formation (Cho et al., 2017).
Genetically, replacement of G6pc via recombinant adeno-
associated virus (rAAV) vector improved hepatic glucose
homeostasis and autophagic flux, and also restored SIRT1-FoxO
signaling in G6pc−/− mice; although rAAV-mediated hepatic
SIRT1 expression only rescued the autophagy abnormalities but
not the metabolic defects (Cho et al., 2017). Pharmacologically,
inducing autophagy with rapamycin reduced hepatic triglyceride,
glycogen content and necrosis in the liver of G6pc−/− mice,
diminished liver size and markers of liver damage in GSDIa
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dogs that were homozygous for an inactivating mutation in
G6pc (Farah et al., 2016), and decreased ER stress in the kidney
of G6pc−/− mice (Farah et al., 2017). In adult (older) mice,
however, rapamycin could not rescue the defective autophagic
flux in the liver but only marginally increased autophagosome
formation (Cho et al., 2017). This study suggested that the
differences between these two responses to rapamycin in the
liver is thought to be due to the age of the mice as the
hepatic gene expression regulated by mTOR differs depending
on developmental stages and age (Boylan et al., 2015; Cho
et al., 2017). Furthermore, a pan-PPAR (peroxisome proliferator-
activated receptor) agonist called bezafibrate, a lipid-lowering
drug used for treating hyperlipidemia, was shown to reduce liver
triglyceride and glycogen levels, induce mitochondrial biogenesis
and improve autophagic flux in G6pc−/− mice (Waskowicz et al.,
2019). Since PPARα agonists such as Wy-14 643 and GW7647
could stimulate hepatic lipophagy and attenuate liver injury
in mice and patients with acute liver failure (Jiao et al., 2014;
Lee J.M. et al., 2014), modulation of PPARα (a nutrient-sensing
nuclear receptor) for inducing hepatic autophagy might represent
a potential therapeutic target for the treatment of GSDIa.
THE ROLE OF AUTOPHAGY IN LIPID
STORAGE DISORDERS
Autophagy is a major clearance route for intracellular lipids
via a process termed lipophagy. This is evident from genetic
ablation of autophagy in mice that increased triglyceride
content and lipid droplets (Singh et al., 2009). However, the
exact mechanism of selectively targeting the lipid droplets for
autophagic degradation is not clear. In lipid storage disorders,
malfunction of autophagy could thus contribute to the disease
pathology (Ward et al., 2016).
Gaucher Disease
Gaucher disease (GD) is an autosomal recessive lysosomal
storage disorder associated with neurological damage and
hepatosplenomegaly. GD is characterized by mutations in GBA1
gene encoding for glucocerebrosidase (GCase), an enzyme that
hydrolyses glucosylceramide; and in rare cases by mutations
in PSAP gene that leads to deficiency of the GCase activator,
saposin C (Stirnemann et al., 2017). Lysosomal accumulation
of glucosylceramide and glucosylsphingosine in GD is thought
to impair autophagy in the late stages (Figure 2). Indeed,
a block in autophagic flux associated with accumulation of
autophagy substrates, ubiquitinated proteins, autophagosomes,
and inefficient cathepsin activity, was seen in mice, flies, patient
fibroblasts and iPSC-derived neuronal models of GD with GCase
or saposin C deficiency (Sun et al., 2010; Vaccaro et al., 2010;
Tatti et al., 2012; Osellame et al., 2013; Farfel-Becker et al., 2014;
Awad et al., 2015; de la Mata et al., 2015). Defective mitophagy,
mitochondrial dysfunction and oxidative stress were also found
in GD that are likely consequences of impaired autophagy
(Cleeter et al., 2013; Osellame et al., 2013; de la Mata et al., 2015;
Kinghorn et al., 2016; Li et al., 2019).
Interestingly, mutations in GBA1 gene could induce
neurodegeneration and correlated with increased risk of
developing Parkinson’s disease (PD) (Sidransky et al., 2009;
Farfel-Becker et al., 2014). This is because GCase and α-synuclein
form a pathogenic loop wherein GCase deficiency (in GD)
caused autophagic dysfunction and α-synuclein accumulation
whereas overexpression of α-synuclein (in idiopathic PD) could
disrupt GCase trafficking and activity (Mazzulli et al., 2011;
Schondorf et al., 2014; Du et al., 2015; Magalhaes et al., 2016).
In a Drosophila model of neuronopathic GD, decreased mTOR
activity and upregulation of the fly ortholog of mammalian
TFEB was observed, which is thought to work as a compensatory
mechanism for overcoming the autophagic block (Kinghorn
et al., 2016). Further inhibition of mTOR with rapamycin
extended the life span and rescued the disease pathogenesis in
GD flies (Kinghorn et al., 2016). Contrary to these fly data, GD
patient-specific iPSC-derived neurons exhibited downregulation
of TFEB and lysosomal genes, where rapamycin treatment
caused cell death (Awad et al., 2015). However, recombinant
GCase rescued the defective autophagy and lysosomal depletion
phenotypes in these disease-affected neurons; effects that were
augmented by TFEB overexpression but not on its own (Awad
et al., 2015). It is plausible that induction of autophagy in the
presence of lysosomal dysfunction might be detrimental in
disease-affected neurons, however, various mTOR-independent
autophagy inducers need to be assessed in GD neurons to make
this conclusion.
Niemann-Pick Type C Disease
Niemann-Pick type C (NPC) disease is an autosomal
recessive, lysosomal storage disorder associated with severe
neurodegeneration and hepatosplenomegaly. It is caused by
mutations in NPC1 gene (95% cases; NPC1 disease) or NPC2
gene (5% cases; NPC2 disease) (Vanier, 2010). NPC1 (lysosomal
cholesterol transporter) and NPC2 (lysosomal glycoprotein)
proteins are suggested to facilitate cholesterol transport from the
late endosomal/lysosomal compartments, and their mutations
cause accumulation of unesterified cholesterol in the brain and
other tissues (Karten et al., 2009; Kwon et al., 2009). In NPC1
and NPC2 disease, a block in autophagic flux occurs due to
impaired autophagosome maturation (Figure 2) that results
in build-up of autophagosomes and autophagic cargo (Sarkar
et al., 2013; Lee H. et al., 2014; Guo et al., 2016) including
defective mitophagy and mitochondrial function (Ordonez
et al., 2012; Guo et al., 2016); although lysosomal function
was not overtly compromised (Sarkar et al., 2013). Various
mechanisms underlying autophagy defect in NPC1 disease have
been described using mutant mice, patient fibroblasts and iPSC-
derived neuronal models. These include failure in the SNARE
machinery between autophagosomal Syntaxin-17 and late
endosomal/lysosomal VAMP8 to prevent vesicle fusion (Fraldi
et al., 2010; Sarkar et al., 2013), accumulation of sphingosine due
to reduced sphingosine kinase activity and vascular endothelial
growth factor (VEGF) levels (Lee H. et al., 2014), and depletion
of lysosomal Ca2+ stores (Lloyd-Evans et al., 2008) that could
affect autophagy via calcineurin or calpain (Williams et al., 2008;
Medina et al., 2015). Interestingly, the most common NPC1
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mutant (I1061T) is shown to be selectively degraded via ER
autophagy (ER-phagy) and ER-associated protein degradation
(ERAD) (Schultz et al., 2018).
Of therapeutic relevance, autophagy inducers such as
rapamycin and carbamazepine rescued the autophagy defect
and improved cell viability in NPC1 iPSC-derived neuronal
and hepatic cells, whereas trehalose, verapamil and BRD5631
were effective only in neurons (Maetzel et al., 2014; Kuo
et al., 2015). Although the multi-step route of autophagosome
maturation was impaired in NPC1 disease, autophagy induction
restored functional autophagic flux via the bypass mechanism
enabling direct autophagosome–lysosome fusion; but this did
not reduce the cellular cholesterol load (Sarkar et al., 2013).
Strikingly, cholesterol-depleting agents like 2-hydroxypropyl-
β-cyclodextrin, which has advanced in clinical trials, exhibited
further impairment in autophagic flux, neurotoxic effects and
adverse effects in animals (Peake and Vance, 2012; Sarkar et al.,
2013; Vite et al., 2015). However, β-cyclodextrin derivatives
such as methyl-β-cyclodextrin or β-cyclodextrin-threaded
biocleavable polyrotaxanes could rescue the autophagy defect
and enhance cholesterol clearance in NPC1 cells (Tamura
and Yui, 2015; Dai et al., 2017); although the effect on
autophagy may not be their primary roles. Future directions
may include efficacy studies of combination treatment involving
autophagy inducer and a low-dose of cholesterol-depleting
agent in mouse models.
Fabry Disease
Fabry disease (FD) is a X-linked lysosomal storage disorder
characterized by mutations in the GLA gene on the X
chromosome encoding the lysosomal enzyme, α-galactosidase
A (α-Gal A). FD is associated with impaired glycosphingolipid
metabolism, lysosomal accumulation of a particular fat called
globotriaosylceramide (Gb3) and multi-organ dysfunction
(Germain, 2010). Autophagic flux is impaired in FD possibly
due to defective autophagosome maturation (Figure 2), as
evident from accumulation of autophagosomes, lysosomes and
autophagy substrates in patient fibroblasts, human podocyte
model and α-Gal A deficient mice (Chevrier et al., 2010;
Liebau et al., 2013; Nelson et al., 2014). However, build-
up of autophagosomes may also occur due to increased
biogenesis because FD podocytes displayed inhibition of
mTOR and increased expression of autophagy initiation
genes, BECN1 and GABARAP (Liebau et al., 2013; Braun
et al., 2019). Autophagy dysfunction has been suggested to
contribute to the neuropathological manifestations of FD, and
also to podocyte damage in the kidneys resulting in end-
stage renal disease that is a common cause of death in FD
(Liebau et al., 2013; Nelson et al., 2014). In female patient
fibroblasts, the disease severity correlated with the extent of
impaired autophagy (Yanagisawa et al., 2019). The autophagy
dysfunction is thought to interfere with the efficiency of ERT
in FD podocytes (Chevrier et al., 2010); a phenomenon also
reported in Pompe disease. Therefore, ERT coupled with
induction of autophagy could be evaluated to improve the
disease outcome.
CONCLUDING REMARKS
Autophagy is responsible for the maintenance of cellular
homeostasis, and the functionality of this vital process is
impaired in different ways in myriad macromolecule storage
disorders associated with accumulation of aggregation-prone
proteins, carbohydrates and lipids. Beyond the pathologies
outlined in this review, autophagy has been implicated in several
other macromolecule storage disorders including amyotrophic
lateral sclerosis and polyglutamine diseases associated with
build-up of aggregation-prone proteins (Menzies et al., 2017),
and neuronal ceroid lipofuscinosis associated with build-up of
lipofuscin that are lipopigment materials made up of lipids
and proteins (Seranova et al., 2017). Defective autophagy
reported in many such conditions has been suggested to
contribute to the disease pathology, whereas in certain instances,
stimulation of autophagy is beneficial which could reduce the
macromolecular burden and prevent cytotoxicity. Autophagy
inducing-compounds have been shown to attenuate the disease
phenotype in various cell, fly and mouse models of these
diseases where the lysosomal degradative capability if not overtly
compromised. Modulation of autophagy by small molecules
might thus represent an attractive therapeutic strategy in
macromolecule storage disorders, but disease-specific treatments
must be thoroughly researched because some of the conditions
might require a combination of autophagy inducer and
conventional therapy.
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